N/A N=24 Acupuncture in Myasthenia Gravis (AcuMG)
Myasthenia Gravis
Primary: To Determine the Effect of Acupuncture on Quality of Life in Patients With MG — 10.8; 9.4; 3.6; 8.3 score on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=488 BEhavioral EConomics for Oral Health iNnovation Trial
Toothbrushing · Dental Plaque · Parent-Child Relations
Primary: Toothbrushing Performance — 4.6; 5.6 qualifying half-day episodes per week
N/A N=72 Using Technology-Assisted Stepped Care Intervention to Improve Adherence in Adolescents With Asthma
Asthma
Primary: Percent Change in Inhaler Adherence Via Electronic Monitoring — 14.05; 13.43 percent — p=<0.001
N/A N=272 Clinical and Hospital Stay Effects of Reiki and Manual Therapy After Open Heart Surgery
Coronary Artery Diseases · Valvular Heart Diseases
Primary: Depression — 0.31; 0.42 score on a scale
Phase 4 N=183 A Long-Term Extension Study for Participants With Treatment-resistant Major Depressive Disorder Who Are Continuing Esketamine Nasal Spray Treatment
Depressive Disorder, Major
Primary: Percentage of Participants With Treatment-emergent Adverse Events (TEAEs) — 88.0 percentage of participants
Phase 3 N=722 Study of Recombinant Protein Vaccines With Adjuvant as a Primary Series and as a Booster Dose Against COVID-19 in Adults 18 Years of Age and Older
COVID-19
Primary: Phase 2 and Phase 3 (Cohorts 1, 2 and Comparator): Number of Participants With Immediate Unsolicited Adverse Events (AEs) — 2; 1; 1; 0 Participants
Phase 2 N=9 Improving Ventilatory Capacity in Those With Chronic High Level SCI
Spinal Cord Injuries
Primary: Pulmonary Function — 3.59; 3.77 L
N/A N=1,114 COVID-19 Antibody and Reinfection Study
COVID-19 Testing
Primary: Reinfection With SARS-CoV-2 — 12; 77; 68; 957 Participants
N/A N=3,087 Spine Pain INtervention to Enhance Care Quality And Reduce Expenditure
Back Pain · Neck Pain
Primary: Spine-related Cost of Care at One Year — 1587; 1448; 2528 dollars — p=.04
Phase 3 N=566 An Open-label Study to Assess the Long-term Safety, Tolerability, and Efficacy of KarXT in Adult Patients With Schizophrenia (EMERGENT-5)
Schizophrenia
Primary: Number of Participants With Treatment Emergent Adverse Events (TEAEs) — 466 Participants
Phase 4 N=48 Defining Predictors of RT Response to Vedolizumab in IBD
Crohn Disease of Small Intestine
Primary: Radiological Response — 21; 16 participants
N/A N=27 Financial Incentives to Promote Stimulant Abstinence in a Community-Based Syringe Exchange Program
Stimulant Use
Primary: Stimulant Free Urine Sample — 6.1; 23.6 % stimulant-negative urine drug test
Phase 3 N=30 Development of Ingestible Biosensors to Enhance PrEP Adherence in Substance Users (PrEPSteps)
HIV Infections · Substance Use Disorders
Primary: Feasibility of the Adherence Intervention Qualitative and Quantitive Questionnaire — 14; 14 Participants
Phase 3 N=148 Tandem Auto Stem Cell Transplant With Melphalan Followed by Melphalan and Bortezomib in Patients With Multiple Myeloma
Multiple Myeloma · Auto Stem Cell Transplant
Primary: To Determine the Progression-free Survival of Patients With Multiple Myeloma Treated With Tandem Cycles of High-dose Melphalan Followed by High-dose Melphalan in…
Phase 2 N=385 A Trial of 10 and 30 mg Doses of CVL-231 (Emraclidine) in Participants With Schizophrenia
Schizophrenia
Primary: Change From Baseline at Week 6 in the Positive and Negative Syndrome Scale (PANSS) Total Score — -13.5; -14.7; -16.5 units on a scale — p==0.1765